Drug reps skimp on side effects info
Drug reps hardly ever discuss side effects properly when visiting GPs, and the GPs don't necessarily notice, a study finds.
Just 1.7% of drug promotions provide sufficient information about a drug's safety, an analysis of visits to GPs in the Canada, the US and France showed.
Even for drugs carrying "black box" safety warnings, just 43% of promotions mentioned any potential for harm.
For rosiglitazone (Avandia), for example, some reps overtly claimed the drug was safe, even